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A new Ni(II) complex, [Ni(L)(H2O)] (1), with diethyl 3,30-(2,20-(1,10-(pyridine-2,6-diyl)bis(ethan-1-yl-1-
ylidene))bis(hydrazin-1-yl-2-ylidene))bis(3-oxopropanoate) ligand (H2L) was synthesized as a potential
chemotherapeutic agent. Polidentate ligand was coordinated to Ni(II) NNN-tridentately, in dianionic form,
while monodentate water coordination completed square-planar geometry around metal. Structure in
the solution was determined by NMR spectroscopy and the same coordination mode was observed in
the solid state using IR spectroscopy and further veriﬁed by DFT calculations and electrochemical
studies. Thermal stability of 1 was determined in both air and nitrogen atmosphere. Anticancer activity of
1 was investigated on acute monocytic leukemia (THP-1) and pancreatic adenocarcinoma (AsPC-1) cell
lines. On THP-1 cells 1 induced powerful apoptotic response (ED50 ¼ 10  3 mM), which was revealed to
be only partially caspase-dependent, with activation of caspase-8 as the dominant course. This
suggested that experimentally validated covalent binding of 1 to DNA is not the only mechanism
responsible for programmed cell death. This was supported with experiments on AsPC-1 cells. Although
treatment of those cells with 1 resulted in poor apoptotic response, cell cycle changes showed
concentration-dependent shifts indicating a dual mechanism of activity. This study also reviews the
results of preliminary biological screening, which demonstrates that 1 displays a unique pattern of
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8740Introduction
Ni(II) complexes with hydrazone ligands have been a focus of
intense research, due to their application in hydrogen produc-
tion1 and catalysis,2,3 as well as their magnetic properties,2,4
application for data storage5,6 and as ame retardants.7Nickel is
an essential micronutrient in many microorganisms, and
enzymes involved in several critical metabolic processes contain
nickel as a co-factor,8 making nickel complexes a subject of
many biological studies.9,10 On the other hand, hydrazone
ligands create the local environment similar to that in the bio-
logical systems – coordination through O and N atoms to
ametal center, and their –NH and –CO groups can participate in
hydrogen bonding and represent potential deprotonation-
protonation sites.11 Inorganic medicinal chemistry is
a growing eld, investigating use of metal complexes in drug
discovery. Complex formation results in species with novel
structural scaﬀolds and electronic properties that are not
accessible through organic compounds. The important property
of these metal complexes is the ability to undergo ligandThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineexchange reaction with biomolecules, making them DNA,
protein and enzyme targeting molecules, which display activity
against diseases such as cancer, diabetes, anti-inammatory
disorders, neurological disorder and infectious diseases. The
structure of these complexes depends on the nature of the
organic ligands and the oxidation state of the metal center.12–14
Hydrazone complexes of Ni exhibit a wide spectrum of bio-
logical activity,11 and a number of these complexes have shown
higher anti-cancer activity than the drugs approved for treat-
ment of certain types of cancer.15–29 Ni(II) ion has d8 electronic
conguration, same as Pt(II) – the metal ion in, so far, all of the
approved anti-cancer treatment drugs: cisplatin (CDDP), car-
boplatin, oxaliplatin, nedaplatin, and lobaplatin.30 Unlike Pt(II),
which only exhibits square-planar geometry (coordination
number four), Ni(II) oen exhibits higher coordination
numbers, oﬀering greater variation in geometry.
A choice of ligand can dictate square-planar geometry of
Ni(II) hydrazone complexes, like dihydrazone ligands obtained
from 2,6-diacetylpyridine (dap) and various hydrazone deriva-
tives which coordinate asymmetrically to Ni(II) building square-
planar complexes.31–36 N-Acylhydrazone (NAH) moiety has been
characterized as a privileged structure in anticancer research.37
Molecules containing NAH moiety can be prepared by
condensation of carbonyl compounds with malonic acid dyhi-
drazide (dhm), resulting in dyhidrazones and their complexes,
which show promising anticancer activity.38–42 It is well known
that condensation reaction between dap and dhm yields
macrocyclic dyhidrazone, which forms an octahedral complex
with Ni(II). In order to prevent the formation of macrocyclic
dyhidrazone based on dap, we introduced a new N-acylhy-
drazide, ethyl 3-hydrazino-3-oxopropionate (emh), in anticancer
research by replacing one of hydrazide group in dhm with ester
group. Here we present the synthesis of a new square-planar
Ni(II) complex [Ni(L)(H2O)] (1) with the in situ obtained diethyl
3,30-(2,20-(1,10-(pyridine-2,6-diyl)bis(ethan-1-yl-1-ylidene))bis-
(hydrazin-1-yl-2-ylidene))bis(3-oxopropanoate) ligand (H2L),
which is a product of condensation of dap with emh and its
characterization in both the solid state and the solution.
Thermal stability of this complex was investigated and its anti-
cancer activity was compared to CDDP, with a study of its
interaction with DNA in order to understand its reaction
mechanism in biological systems. To the best of our knowledge,
this is the rst anti-cancer study of a bishydrazone square-
planar complex of Ni(II) containing dap.
Experimental
General remarks
Hydrazine hydrate (55%) and dap (99%) were obtained from
Acros Organics, while diethyl malonate (98%) was obtained
fromMerck. Solvents (ethanol 96% and diethyl ether) were used
without further purication. Elemental analyses (C, H, N) were
performed by the standard micro-methods using the ELE-
MENTAR Vario ELIII C.H.N.S¼O analyzer. Infra-red (IR) spectra
were recorded on a Thermo Scientic Nicolet 6700 FT-IR spec-
trophotometer by the Attenuated Total Reection (ATR) tech-
nique in the region 4000–400 cm1. Abbreviations used for theThis journal is © The Royal Society of Chemistry 2016IR spectra interpretation are: s (strong) andm (medium strong).
Molar conductivity measurements were performed at ambient
temperature on the CrisonMultimeter MM41 in methanol (c¼ 1
 103 mol dm3). The ligand coordination mode in the
complex was determined by NMR spectroscopy results: 1D (1H
and 13C), 2D COSY, 2D NOESY and 2D ROESY, as well as 2D
heteronuclear correlation HSQC and HMBC. The NMR spectra
were obtained on BrukerAvance 500 equipped with broad-band
direct probe. All spectra were measured at 298 K in CDCl3.
Chemical shis are given on d scale relative to tetramethylsilane
as an internal standard for 1H and 13C. Abbreviations used for
1H NMR spectrum: s, singlet; d, doublet; t, triplet; q, quartet.
Electron spray ionization mass spectrum (ESI-MS) was recorded
on LTQ Orbitrap XL spectrometer in a positive ion mode. UV-Vis
spectrum was recorded on Shimadzu PharmaSpec UV-1700
spectrophotometer. Melting points were recorded on Stuart
SMP10 without correction.
Synthesis of emh
Emh was synthesized according to the previously published
method.34 Product was recrystallized from ethanol. Melting
point of the product (69–72 C) is in good agreement to data
previously published (68–69 C).43
Synthesis of 1
Into the solution of dap (0.3 g, 1.839  103 mol) and emh
(0.54 g, 3.675  103 mol) in ethanol (60 mL), Ni(CH3COO)2-
$4H2O (0.45 g, 1.839  103 mol) was added. The reaction
mixture was reuxed for 45 min and cooled to ambient
temperature. Three days later red precipitate was ltered oﬀ,
washed with ethanol and diethyl ether and dried in a desiccator.
Yield: 0.27 g (29.7%). Mp ¼ 180–182 C. Anal. calcd for
C19H25N5NiO7 (%): C, 46.18; H, 5.10; N, 14.17%. Found: C,
46.18; H, 4.92; N, 14.34%. LM (1  103 M, MeOH): 1.20 U1
cm2 mol1. IR (ATR, cm1): 3559 (s) n(O–H); 1733 and 1673 (s)
n(C]O); 1635 (m) n(C]N). 1H NMR (500.26 MHz, CDCl3), d:
8.44 (t, 1H, H–C3, 3J3,2 ¼ 3J3,2 ¼ 7.9 Hz), 7.97 (d, 1H, H–C2, 3J2,3
¼ 7.9 Hz), 7.83 (d, 1H, H–C4, 3J4,3 ¼ 7.9 Hz), 4.25 (q, 2H, H–C11,
3J11,12¼ 7.1 Hz), 4.17 (q, 2H, H–C18, 3J18,19¼ 7.1 Hz), 3.72 (s, 2H,
H–C16), 3.44 (s, 2H, H–C9), 2.43 (s, 3H, H–C14), 2.29 (s, 3H, H–
C7), 2.11 (s, 2H, H2O), 1.33 (t, 3H, H–C12,
3J11,12 ¼ 7.1 Hz), 1.29
(t, H–C19, 3H, 3J18,19¼ 7.1 Hz); 13C NMR (125.80MHz, CDCl3), d:
182.10 (C8), 178.04 (C15), 169.76 (C17), 168.60 (C10), 156.23
(C5), 153.08 (C6), 141.60 (C3), 137.80 (C1), 131.57 (C13), 124.64
(C2), 123.19 (C4), 61.29 (C11), 60.58 (C18), 45.48 (C16), 37.96
(C9), 20.98 (C14), 14.18 (C12), 14.11 (C19), 12.06 (C7). ESI-MS:
[M  H2O + H+]+ (C19H24N5NiO6) calcd. m/z 476.1080, found
476.1069.
Thermal analysis
Non-isothermal diﬀerential scanning calorimetry (DSC)
measurements in nitrogen were carried out using DSC Q1000
(TA Instruments) with typical sample weight of 2.0  0.2 mg, in
nitrogen atmosphere with gas ow rate of 50 mL min1, in 25–
300 C temperature region. Non-isothermal thermal gravimetric
analysis (TG) in air was conducted using PerkinElmerRSC Adv., 2016, 6, 108726–108740 | 108727
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View Article OnlinePyrisDiamond TG/DTA, which provides simultaneous TG, DTG,
DTA and DSC data. The measurements were conducted with air
ow rate of 150 mL min1, in 25–600 C range at diﬀerent
heating rates. TG measurement in nitrogen was conducted
using the same instrument in 25–1000 C range, with nitrogen
ow rate of 150 mL min1. Calibration of thermal analysis
instruments was conducted for each heating rate separately.
Analysis of thermal data was conducted using ThermV soware
package 0.2.44
Cyclic voltammetry (CV)
CV measurements were performed using an electrochemical
system CH Instruments (USA). The electrochemical cell (10 mL)
consisted of a three-electrode system: glassy carbon electrode
(inner diameter of 3 mm; CHI 104), an Ag/AgCl (saturated KCl)
reference electrode and Pt counter electrode. The potential was
swept over the range from 2.5 to +1.5 V (vs. Ag/AgCl) at scan
rate of 100 mV s1. Measurements were performed at room
temperature with deaeration of the solutions by passing
a stream of nitrogen through the solution for 5 min and
maintaining a blanket atmosphere of nitrogen over the solution
during the measurement. The potentials were measured, and
are quoted relative to Ag/AgCl reference electrode.
DFT calculations
DFT calculations on molecular systems were performed using
Gaussian 09 rev. D45 and ORCA v3.0.2 (ref. 46) program pack-
ages. Gaussian package was used for structure optimization and
frequency analysis. All structures where fully optimized using C-
PCM solvation method with Klamt radii.47 In calculations we
used the hybrid HF/DFT method with a combination of the
three-parameter Becke48 exchange functional and the Lee–
Yang–Parr (B3LYP)49 non-local correlation functional and Beck's
exchange functional combined with Perdew's50 (BP86) non-local
correlation functional. ORCA package was employed for
constraint relaxed surface scan at same theoretical level as in
Gaussian 09, using COSMO solvation model. In addition, for
calculations with ORCA package, exchange and correlation
functional of Perdew, Burke and Ernzerhof (PBE)51,52 were used.
For the metal center LANL2DZ basis set was used in Gaussian
and TZVP in ORCA, while 6-31G(d,p) basis set was used for the
rest of the atoms in both Gaussian and ORCA calculations. IR
spectrum was calculated using the molecular system in water
solvent, while TD-DFT calculation of this system was per-
formed, calculating 50 states, to obtain the calculated UV-Vis
spectrum. Elucidation of vibrational spectra of calculated
structures was conducted using potential energy distribution
(PED) analysis implemented in VEDA package.53
Interactions with DNA
Fluorescence displacement experiments. A calf thymus
DNA(CT-DNA; lyophilized, highly polymerized, Serva, Heidel-
berg) was dissolved in Tris buﬀer (10 mM Tris–HCl pH 7.9)
overnight at 4 C. This stock solution was stored at 4 C and was
stable for several days. A solution of CT-DNA in water gave
a ratio of UV absorbance at 260 and 280 nm, A260/A280 of 1.89–108728 | RSC Adv., 2016, 6, 108726–1087402.01, indicating that DNA was suﬃciently free of protein. The
concentration of DNA (2.86 mg mL1) was determined from the
UV absorbance at 260 nm using the extinction coeﬃcient 3260 ¼
6600 M1 cm1.54 UV-Vis spectrum was recorded on a UV-1800
Shimadzu UV/Visible spectrometer operating from 200 to
800 nm in 1.0 cm quartz cells.
The competitive interactions of 1 and the uorescence
probes, Hoechst 33258 (H) and ethidium bromide (EB) with CT-
DNA have been studied by measuring the change of uores-
cence intensity of the probe-DNA solution aer addition of 1.
Reactionmixtures containing 100 mMof CT-DNA (calculated per
phosphate) in 1 mL of 40 mM bicarbonate solution (pH 8.4)
were pretreated with 1 mL of the probe solution (25 mMof EB and
28 mM of H at nal concentrations) for 20 min and the mixture
was analyzed by uorescence measurement. Then the gradually
increasing concentrations of the complex (nal concentrations
2, 4, 6, 8 10, 12, 16, and 20 mM) successively added and the
change in the uorescence intensity was measured using
a Thermo Scientic Lumina Fluorescence spectrometer (Fin-
land) equipped with a 150 W Xenon lamp. The slits on the
excitation and emission beams were xed at 10 nm. All
measurements were performed by excitation at 500 nm in the
range 520–700 nm for EB and by excitation at 350 nm in the
range 390–600 nm for H. The control was the probe–CT-DNA
solution. 1 did not have uorescence under applied conditions.
Thermal denaturation. Thermal denaturation experiments
were carried out by monitoring the absorption intensity of the
CT-DNA at 260 nm varying the temperature from 60 to 100 C in
the absence and presence of the complex at ratio 2 : 1 with ramp
rate of 1 C min1 in 10 mM phosphate buﬀer (pH 7.0) in
CINTRA 40 UV-Vis spectrometer equipped with a Peltier
element.
Electrophoretic mobility shi assay. The plasmid pUC19
(2686 bp, Sigma-Aldrich, USA) was prepared by its trans-
formation in chemically competent cells Escherichia coli strain
XL1 blue. Amplication of the clone was done according to the
protocol for growing E. coli culture overnight in LB medium at
37 C (ref. 55) and purication was performed using Qiagen
Plasmid plus Maxi kit. Finally, DNA was eluted in 10 mM Tris–
HCl buﬀer and stored at 20 C. The concentration of plasmid
DNA (512 ng mL1) was determined by measuring the absor-
bance of the DNA-containing solution at 260 nm. One optical
unit corresponds to 50 mg mL1 of double stranded DNA.
Supercoiled pUC19 DNA (512 ng) was subjected to diﬀerent
concentrations of 1 was investigated and incubated in a 20 mL
reaction mixture in 40 mM bicarbonate buﬀer (pH 8.4) at 37 C,
for 90 min. The reaction mixtures were vortexed from time to
time. The reaction was terminated by short centrifugation at
6708g and the addition of 5 mL of loading buﬀer [0.25% bro-
mophenol blue, 0.25% xylene cyanol FF and 30% glycerol in
TAE buﬀer, pH 8.24 (40 mM Tris–acetate, 1 mM EDTA)].
The samples were subjected to electrophoresis on 1%
agarose gel (Amersham Pharmacia-Biotech, Inc) prepared in
TAE buﬀer (pH 8.24). The electrophoresis was performed at
a constant voltage (80 V) until bromophenol blue had passed
through 75% of the gel. A Submarine Mini-gel Electrophoresis
Unit (Hoeﬀer HE 33) with an EPS 300 power supply was used.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineAer electrophoresis, the gel was stained for 30 min by soaking
it in an aqueous EB solution (0.5 mg mL1). The stained gel was
illuminated under a UV transilluminator Vilber-Lourmat
(France) at 312 nm and photographed with a Nikon Coolpix
P340 Digital Camera through lter DEEP YELLOW 15 (TIFFEN,
USA).
Cell cultures. Acute monocytic leukemia (THP-1, ATCC® TIB-
202) and pancreatic adenocarcinoma (AsPC-1, ATCC® CRL-
1682) cell lines were maintained in RPMI-1640 (Life Technolo-
gies, 11875-093) and DMEM high glucose (Sigma-Aldrich,
D5796) cell culture media, respectively. Both media were sup-
plemented with 10% (v/v) fetal bovine serum (FBS, Gibco, Cat.
no. 16000-036) and 1% (v/v) penicillin–streptomycin (10 000
units per mL and 10 000 mg mL1, Gibco, Cat. # 15140-130).
Cells were kept at 37 C in atmosphere containing 5% (v/v) CO2
during their exponential growth and during the course of
experimental treatments.
Investigated compound was initially dissolved in dimethyl
sulfoxide (DMSO) to the stock concentration of 20 mM. Further
dilutions to the experimental concentrations applied on the
cells have been done with RPMI-1640 or DMEM media imme-
diately before each experiment, so that the highest nal DMSO
concentration never exceeded 0.5% (v/v).
Determination of pro-apoptotic activity. THP-1 and AsPC-1
cells were seeded in 96 at bottom well plates (Corning®
Costar®, Cat. no. CLS3596) in a volume 0.1 mL, at a density of
10 000 cells per well. Since the THP-1 cells grow in suspension,
experimental treatments started within 2 h aer cells seeding,
while plates with adherent AsPC-1 cells were le overnight to
settle. Investigated compound was added in a range of six rising
concentrations. As controls, non-treated cells, cells treated with
0.5% DMSO, and cells treated with Celestrol (Enzo Life
Sciences, Cat. no. ALX-350-332-M025) at 50 mM concentration
were present in each 96-well plate.
Aer 24 h of incubation, THP-1 cells were centrifuged on
450g for 10 min, supernatants were discarded, and 0.1 mL of
phosphate buﬀer saline (PBS) was added to each well. Plates
were places on plate shaker for 3 min, aerwards Annexin V-
FITC (ImmunoTools, Cat. no. 31490013) and propidium
iodide (PI, MiltenylBiotec, Cat. no. 130-093-233) were added in
a volume of 3 mL per well, respectively, and incubated for 15 min
in the dark prior to cytometry. Post incubation manipulation
with AsPC-1 cells included transfer of supernatant mediumwith
non-adherent cells into another plate. Fresh PBS was added to
remaining adherent cells aerwards the plates were centrifuged
at 450g for 10 min. Supernatant was discarded and 200 mL of
trypsin–EDTA (BioWest, Nuaille, France, Cat. No L0930-100)
was added to each well. Cells were detached in about 15 min
of incubation at 37 C, aerwards another spinning cycle with
supernatant elimination were performed. Finally, previously
removed supernatant with non-adherent cells were added to
trypsinized cells and stained with Annexin V-FITC and PI in
a volumes of 3 mL. Plate analysis were performed on Guava®
easyCyte 12HT Benchtop ow microcapillary cytometerusing
InCyte® soware package (EMD Millipore, Cat. no. 0500-4120).
Cells were classied according to Annexin V and PI labeling on
viable (non-stained cells), pre-apoptotic cells (stained withThis journal is © The Royal Society of Chemistry 2016Annexin V only), cells in late phases of apoptosis (double
stained cells), and necrotic cells (stained with PI only).
Calculation of ED50 concentration. Percent of Annexin V
labeled cells for each concentration of investigated compound
were summarized and maximum apoptotic response was
normalized to 100%. Percent of apoptosis read out for other
concentrations were calculated as a proportion of the highest
response. Such scaled apoptotic outcomes were plotted against
concentrations and ED50 concentration was calculated using
asymmetric sigmoidal curve ve-parameter logistic equation
(GraphPad Prism 6 soware). Determined ED50 concentration
was applied in further steps of this investigation.
Cell cycle analysis. Cell cycle was evaluated either aer cells
were treated with ED50 concentration of the investigated
compound for diﬀerent time periods (6, 9, 12 and 24 h), or on
cells already stained by Annexin V/PI readout as described
previously.56 In both cases, treated cells were xed in ethanol
overnight at 4 C and then labeled by the FxCycle™ PI/RNAse
Staining solution (Molecular Probes, Cat. no. F10797). Anal-
yses were all performed on Guava® easyCyte 12HT Benchtop
Flow microcapillary cytometer.
Inhibition of caspase activity. Cells were treated with inves-
tigated compound at ED50 concentration for 6 h with or without
pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp (O–Me)
uoromethyl ketone (Z-VAD-fmk, Promega, Cat. no. G7232). As
controls, non-treated cells, cells treated with Z-VAD-fmk only,
and cells treated with ED50 concentration only were used. Aer
incubation period was ended, treated cells were carried out for
Annexin V/PI staining as described above, and analyzed on
Guava® easyCyte 12HT cytometer. The percent of apoptosis
inhibited by Z-VAD-fmk co-treatment was determined by
following formula:
% of inhibition ¼ [1  (% of apoptosis or necrosis in A/
% of apoptosis or necrosis in B)]  100% (1)
where A is the sample treated with both ED50 concentration and
Z-VAD-fmk, and B the corresponding sample treated with ED50
concentration only.
Evaluation of caspase-8 and -9 activities. Cells were treated
with investigated compound at ED50 concentration for 6 h
aerwards activity of caspase-8 and -9 were assayed by means
of Guava Caspase 9 SR and Caspase 8 FAM kit (EMD Millipore,
Cat. no. 4500-0640), following instructions of manufacturer. In
acquired data cells were discriminated according to expres-
sion of green uorescence (caspase-8), yellow uorescence
(caspase-9), or red uorescence (7-AAD) as the following: live
cells (not stained with either caspase nor 7-AAD); mid stage
apoptotic cells (cells stained with either caspase-8 or -9, but
negative to 7-AAD); late stage apoptotic cells (cells stained with
either of caspase-8 or -9 and with 7-AAD); necrotic cells (cells
not stained with neither caspase-8 nor -9, but positive for 7-
AAD). Percentages of treated cells that express caspase activity
were calculated relative to non-treated control computed
separately for cells which expressed activated either caspase-8
or -9, and cells that showed activity of both caspases using
formula:RSC Adv., 2016, 6, 108726–108740 | 108729
Fig. 1 The optimized structure of 1.
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View Article OnlineRelative activity, % ¼ [% of treated cells expressing caspase(s)/
% of non-treated cells expressing caspase(s)]  100% (2)
Results and discussion
General
Red precipitate of Ni(II) complex was obtained by the template
reaction of dap and emh with Ni(CH3COO)2$4H2O in ethanol
(1 : 2 : 1) (Scheme 1). The product was soluble in methanol,
acetonitrile, chloroform, dimethyl formamide and DMSO,
partially soluble in ethanol and insoluble in diethyl ether and
water. Magnetic measurement indicated that the complex is
diamagnetic, while the value of its molar conductivity in
methanol is 1.20 U1 cm2 mol1, signicantly less than for 1 : 1
electrolytes.57 Elemental analysis showed that the complex
consists of Ni(II) ion, dianionic ligand and one water molecule.
Based on these results, the following general formula can be
written [Ni(L)(H2O)] mass spectrum of the complex recorded in
acetonitrile shows the most intense peak at m/z ¼ 476.1069,
corresponding to the fragment [NiL  H2O + H+]+, with the
appropriate isotope pattern (Fig. S1, ESI†).
Structural and electrochemical studies
1D (1H and 13C) and 2D (COSY, NOESY, 1H–13C HSQC and
1H–13C HMBC) NMR spectra of 1 in CDCl3 are shown in Fig. S2–
S8 (ESI†), while the atom numbering scheme was given in
Scheme 1. The number of signals observed in 13C NMR spec-
trum of 1 (total of 19) indicate asymmetric coordination of L2
to Ni(II), since 10 signals of carbon atoms are expected for
symmetrical coordination of the ligand. In 1H NMR spectrum of
1 11 signals were detected. A signal at 2.11 ppm in 1H NMR
spectrum was assigned to the water molecule coordinated to the
Ni(II) ion. This signal is signicantly shied downeld in
comparison to the signal of non-coordinated water in CDCl3
which appears at 1.56 ppm.58 Similar situation, where respective
solvents had similar polarity to the solvents used in our system,
was observed in square-planar nickel(II) complex with contains
diphosphane ligand and coordinated water molecules, where
structure was solved with single crystal X-ray analysis.59 NMR
study in CD2Cl2 solution determined downeld shi of coor-
dinated water (2.30 ppm) in comparison to non-coordinated
water (1.52 ppm).60 The diﬀerence in chemical shis ofScheme 1 Preparation of the complex [Ni(L)(H2O)] (1).
108730 | RSC Adv., 2016, 6, 108726–10874022.51 ppm between imine carbonyl atoms C6 (153.1) and C13
(131.6) indicated that imine nitrogen N2 is coordinated to Ni(II),
since electron density of C]N bond is shied towards Ni(II).
Diﬀerence in chemical shis of C8 and C15 atoms is not as large
(Dd ¼ 4.06 ppm), indicating that oxygen atoms O2 and O3 do
not participate in the coordination to the metal.
In the 1H NMR spectrum, H–C16 was shied downeld in
comparison to its analogue H–C9, indicating coordination
through N5. The coordination sphere of Ni(II) in this square-
planar environment is completed by coordination of pyridine
nitrogen which is corroborated by DFT calculations (vide infra).
The coordination of pyridine nitrogen is likely to occur, since it
results in formation of two stable chelate rings. Based on this
information, the proposed structure of 1 is given in Scheme 1.
Proposed geometry around Ni(II) in 1 was further conrmed
by theoretical DFT calculations. Independent of the starting
geometry, the complex was always optimized to the slightly
distorted square-planar geometry as shown in Fig. 1. In the
optimized geometry, all three donor atoms from L2, nickel,
and water oxygen atoms are in the same plane. Angles around
Ni(II) are slightly distorted from ideal square-planar geometry
due to steric hindrances in tridentate L2 ligand (angle N1–Ni–This journal is © The Royal Society of Chemistry 2016
Fig. 2 Comparison of experimental and calculated UV-Vis spectra of
1.
Table 1 Electronic spectral data for 1
l (nm) A 3 (M1 cm1) Assignation
439.50 0.1965 196 500 1A2g)
1A1g
341.75 1.0475 1 047 500 1B2g)
1A1g
296.68 0.7143 714 300 1Eg)
1A1g
245.18 1.3807 1 380 700 L) Ni2+
Fig. 3 Experimental and calculated IR spectra of 1.
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View Article OnlineN2 ¼ 84.4; angle N5–Ni–N1 ¼ 96.2). Results of the calculated
1H and 13C NMR spectra of 1 (Tables S1 and S2, ESI†) show good
agreement with experimental data, indicating that the actual
geometry of 1 closely corresponds to the proposed one. The only
signicant deviation comes in the chemical shi of the water
molecule proton, where one of the protons exhibits much
higher chemical shi than observed in the experiment. This can
be explained by the fact that the calculation was performed on
amonomer system in a continuous dielectric, taking no account
of intermolecular interactions. As a consequence, these two
protons exhibit signicantly diﬀerent hydrogen bond lengths
(Fig. 1), and the proton with shorter hydrogen bond exhibits
higher chemical shi.
The experimental spectrum suggests that both water protons
are equivalent, suggesting that the orientation of the molecule
in the solution is most likely such that the hydrogen bonding to
two water protons is achieved either through O6 and O4 oxygen
and not O2 and O3, or through intermolecular hydrogen
bonding, making hydrogen bonds longer. This suggests that the
geometry is probably dictated by intermolecular interactions,
where this orientation would make the entire molecule roughly
planar in the coordination plane of the metal center, providing
better geometry for interactions above and below this plane.
UV-Vis spectrum of 1 in MeOH contains four bands (Fig. 2):
three of them (439.50, 341.75, 296.68 nm) are assigned to
electronic transitions of square-planar Ni(II) complex, and the
fourth (245.18 nm) is assigned to the charge transfer between
the ligand and Ni(II) ion (Table 1). There is a good agreement
between experimental and the normalized calculated UV-Vis
spectrum (with N ¼ 100 calculated transitions) of 1, as shown
in Fig. 2. Since the optimized structure of 1 exhibits square-
planar coordination around the metal center, this represents
another conrmation of the band assignment.
Electrochemical behavior of 1 was investigated using CV on
a glassy carbon working electrode in the potential range from
2.50 to +1.50 V vs. Ag/AgCl electrode in DMSO using [n-Bu4N]This journal is © The Royal Society of Chemistry 2016PF6 as supporting electrolyte. Under these experimental condi-
tions, 1 undergoes irreversible redox processes, giving two
reduction peaks at 1.77 and 2.00 V, and one oxidation peak
at +0.98 V (Fig. S9, ESI†) with the onset of oxidation and
reduction at Eox.onset ¼ +0.68 V and Ered.onset ¼ 1.58 V,
respectively. From these values,61 where ferrocene was used as
an external standard, the energy gap (Eg ¼ ELUMO  EHOMO) was
calculated to be +2.26 eV, which is in good agreement with the
value +2.33 eV, calculated from longest absorption wavelength
lonset (Eg ¼ 1242/lonset)62 and the one obtained by DFT calcula-
tions +2.28 eV. However, DFT calculations gave the values of
EHOMO and ELUMO as 5.78 eV and 3.44 eV, compared to the
experimental values obtained from CV63 of 4.93 and 2.67 eV,
respectively. This signicant diﬀerence between electrochemi-
cally obtained and calculated values is a consequence of high
irreversibility of the observed electrochemical processes. This
can be expected when irreversible electrochemical processes
include, in addition to electronic transition, other limiting
steps, which were not taken into account by the DFT model and
UV spectra as well.
Experimental and calculated IR spectra for 1 are given in
Fig. 3, with full assignment of the bands in Table 2. DFT
calculations on a molecular system in a continuous water
solvent resulted in good agreement between experimental and
calculated IR spectra (Table 2), allowing assignment of the
vibrations in the experimental IR spectrum using the results of
the calculations.RSC Adv., 2016, 6, 108726–108740 | 108731
Table 2 Selected experimental and calculated IR spectral data of 1
Vibration Type
Calculated n
(cm1)
Experimentaln
(cm1)
O–H (water) sym. stretch 3670, 2930 3559, 2939
C]O sym. stretch 1729, 1718 1733.5
O–H (water) sym. scissor 1690 1673
C]N sym. stretch 1640, 1605 1634, 1600
C]N sym. stretch 1590, 1560 1600, 1577
Ring vibration sym. ring vibr. 1559 1525
C–H sym. def. 1350, 1320 1363, 1313
C–O–C (ester) asym. stretch 1229, 1208 1232, 1210
N–N sym. stretch 1150 1156
O–H Rocking 960 955
Ring vibration asym. ringvibr. 860 854.6
O–H (water) asym. 801 807
C–C sym. stretch 722.5 728
Table 3 Enthalpies of the endothermic peak 1 and the exothermic
peak 2 recorded in air and nitrogen
Air
Heating rate
(C min1)
Enthalpy –
peak 1 (kJ mol1)
Enthalpy –
peak 2 (kJ mol1)
2 32.36 5736.76
4 42.55 6425.90
6 48.59 6665.53
10 80.95 7096.12
Nitrogen
Heating rate
(C min1)
Enthalpy –
peak 1 (kJ mol1)
4 12.56
5 20.91
10 29.69
15 33.30
20 36.1
35 33.57
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View Article OnlineThermal analysis
Thermal stability of 1 was analyzed in both air and nitrogen
atmosphere using TG and DSC. TG thermal degradation curves
of 1 in air and nitrogen reveal a signicant diﬀerence of
degradation processes, following diﬀerent reaction pathways in
diﬀerent atmospheres (Fig. 4). Overall, thermal degradation
starts around 200 C and the step-wise mass loss is continuous
until the end of degradation. 1 exhibits considerably faster mass
loss in air, which is consistent with thermally induced oxida-
tion. The nal mass residue is consistent with the formation of
nickel oxide as the nal product: NiO in air and NiO2 or NiOOH
in nitrogen.
DSC of 1 heated in air exhibits an endothermic peak around
180–190 C and a much larger exothermic peak in the 350–
450 C temperature domain (Fig. S13†), both peaks corre-
sponding complex processes involving multiple overlapping
degradation steps. All peaks exhibit a shi to higherFig. 4 TG curves recorded in nitrogen and air.
108732 | RSC Adv., 2016, 6, 108726–108740temperatures with increase in heating rate, indicating thermal
activation of degradation processes.
When 1 was heated in nitrogen, it exhibited an endothermic
process in 180–200 C temperature domain, followed by a series
of exothermic processes in 200–300 C temperature domain
(Fig. S14†). At lower heating rates, the endothermic process
around 180 C is not very well dened due to an overlap with an
exothermic process, which follows. This complex region is fol-
lowed by another exothermic peak around 220 C. However, due
to diﬀerent thermal activation, the endothermic peak is well
dened at higher heating rates (10–35 Cmin1), with very little
variation in overall enthalpy (Table 3).
Endothermic peak 1 exhibits relatively low values of enthalpy
of the overall process (Table 3), both when recorded in nitrogen
and in air, with higher values in air, and, at a heating rate of
10 Cmin1, the changes in the observed values of enthalpy and
peak shape (Fig. 5B) indicate increasing signicance of diﬀu-
sion of oxygen into the sample. Exothermic peak 2 exhibits very
high values of enthalpy of the overall process, which is consis-
tent with oxidation reaction at high temperature. The value of
enthalpy and asymmetric peak shape indicate a very complex
process involving a large number of atoms and breaking of
several bonds.
The values of the overall activation energy for peaks in
nitrogen and air were calculated using Kissinger and Ozawa
methods.64,65 The experimental peak 1 in nitrogen exhibits
unusually high value of the overall activation energy, most likely
due to the overlap with subsequent exothermic process (Table
4). The value of overall activation energy in air is much smaller,
likely due to the presence of oxygen, which changes the reaction
mechanism of thermal decomposition, ultimately leading to
formation of diﬀerent nal products observed in TG curves in
air and nitrogen. The overall activation energy of peak 2 in air is
very small for a process occurring in 350–450 C temperature
domain and this, combined with a very high value of enthalpy,This journal is © The Royal Society of Chemistry 2016
Fig. 5 Displacement of CT-DNA (100 mM, top line) bound H (25 mM),
panel (A) and EB (28 mM) by 1, panel (B), at increasing ﬁnal concen-
trations (2, 4, 6, 8 10, 12, 16, and 20 mM, curves from top to bottom).
The arrows show that ﬂuorescence intensity decreased with
increasing concentration of the complex. The insets demonstrate
ﬂuorescence quenching curves of H bound to CT-DNA at 444 nm and
EB bound to CT-DNA at lmax ¼ 600 nm by 1, panels (A) and (B),
respectively; r ¼ 1/[CT-DNA].
Table 4 Overall activation energies for the endothermic peak 1 and
the exothermic peak 2 recorded in air and nitrogen
Overall Ea (kJ mol
1) Air peak 1 Air peak 2 N2 peak 1
Kissinger method 290  30 81  5 1120  50
Ozawa method 280  30 87  4 1080  50
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View Article Onlineindicates that organic part of the molecule quickly oxidizes,
most likely forming CO2.
Interactions with DNA
Binding of small molecules with DNA and investigation of
structural aspects of such bindings have turned out to be an
emerging topic of interest from the perspective of medicinal
chemistry, including cancer chemotherapy and development of
new and more eﬃcient therapeutic agents targeted to DNA.45
Transition metal complexes can bind to DNA via both covalent
and/or non-covalent interactions. In general, covalent interac-
tions include coordination to DNA base, sugar and phosphateThis journal is © The Royal Society of Chemistry 2016moieties, while non-covalent interactions include binding to
minor groove, major groove, sugar-phosphate backbone, inter-
calation between the bases and binding to unique DNA struc-
tural motifs such as the three way junction, G-quadruplexes,
cruciforms and hairpins.66 In most cases metal complexes
interact with DNA via minor groove, by intercalation and cova-
lent binding.
Fluorescence quenching studies
Fluorescence spectroscopy is a widely used technique for study
of DNA interaction with metal complexes. Fluorescence
quenching of DNA-H dye adduct by the metal complex is an
established method for determination of its propensity to bind
to the DNA minor groove, and uorescent displacement is
widely used for investigation of intercalative properties of metal
complexes. While H is only weakly uorescent, its uorescence
yield increases signicantly in the presence of DNA. In the case
of minor groove binders, the reduction of uorescence was
found to be 55% or more.67,68 However, the addition of 1 to CT-
DNA caused only 19% reduction in the uorescence intensity of
H-CT-DNA system with maximal applied concentration of the
complex (Fig. 5A), indicating that minor groove is not signi-
cant target for 1.
Fluorescent displacement experiments were carried out with
EB, well known dye which acts as a typical DNA intercalator.69
Binding of EB to CT-DNA was followed by excitation at 500 nm
with uorescence maximum at 600 nm. The emission spectra of
EB bound to CT-DNA in the absence and presence of 1 are given
in Fig. 5B. It was observed that the increase in concentration of
1 causes a continuous decrease in the uorescence intensity of
the band at 600 nm of the EB-CT-DNA system, with the maximal
decrease of 32%. EB uorescence quenching by typical strong
intercalators is almost complete,70–72while the values lower than
50% indicate mechanisms of uorescence quenching diﬀerent
from intercalation.73–75 Addition of 1 would quench the EB
emission by either replacing the DNA-bound EB (if it binds to
DNA more strongly than EB) or by accepting the excited state
electron from EB. Since metal complexes with no extended
planar rings are not expected to displace the intercalatively
bound EB, small reduction of DNA-EB uorescence intensity
indicates that quenching occurs by photo electron-transfer
mechanism.76–78 Previous investigation on a series of Cu(II)
complexes indicated that the ability of the complexes to quench
the EB emission intensity by photo electron-transfer mecha-
nism depends upon their reducibility: the complex with a more
positive redox potential (0.219 V) had the highest ability to
quench the emission intensity of EB. Redox potential of 1 is
even more positive, which indicates its capability to undergo
photo electron-transfer mechanism.79
Thermal denaturation studies
Thermal behavior of DNA in the presence of metal complexes
can give insight into DNA conformational changes with increase
in temperature and the strength of DNA-complex interactions.
The temperature at which half of the DNA sample is melted is
known as the melting temperature (Tm), and it is stronglyRSC Adv., 2016, 6, 108726–108740 | 108733
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View Article Onlinerelated to the stability of the double-helical structure. An
increase in melting temperature indicates that the metal
complex has a stabilizing eﬀect, while a decrease in Tm indi-
cates destabilizing eﬀect. High positive DTm (3–8 C) is char-
acteristic for intercalation type of interaction,72,80,81 while
groove-binding interaction of small molecules with DNA leads
to insignicant changes in Tm.80,82–84 Negative values of DTm
indicate covalent binding.85–87 In the case of 1, the diﬀerence in
melting temperatures DTm (DTm ¼ Tm of free DNA – Tm of DNA-
1) is 4.5 C (Fig. 6), corroborating uorescence quenching
studies which show that 1 does not have a signicant propensity
to minor groove and does not intercalate. Negative value of DTm
indicates that this complex binds covalently to DNA.
Metal complexes which undergo covalent binding to DNA
contain labile ligands which act as good leaving groups, such as
Cl ion,79 water88,89 and solvent molecules.90 Structure of 1
seems suitable for covalent bonding to DNA, since square-
planar Ni complexes are capable to extend their coordination
sphere by coordination of axial ligands, resulting in formation
of octahedral complexes. Also, 1 contains a water molecule
coordinated to Ni(II) ion which is a better leaving group than Cl
ion. It is well known that CDDP, [PtCl2(NH3)2], the most famous
covalent binding anticancer agent, needs to release the chloride
before it binds to DNA. Within the cell, CDDP aquation of one
or both chloride leaving groups occurs and resulting complexes
[Pt(H2O)Cl(NH3)2]
+ and [Pt(H2O)2(NH3)2]
2+ are the actual
species which react with nucleophilic centers of biomolecules.88
Nitrogen atom N7 in guanine residues has a strong aﬃnity
for Ni(II):91 it is 2.3 times more basic than corresponding
nitrogen atom from adenine, which leads to 10 times larger
binding aﬃnity to metal ions.92 Also, comparative binding
experiments of Ni(II) complex containing solvent molecule
bonded to metal centre to adenosine-50-monophosphate and
guanosine-50-monophosphate by ESI-MS and NMR spectros-
copy conrmed that binding tendency of nucleotides is higher
for guanosine nucleotide.90Fig. 6 Melting curves of CT-DNA (100 mM) in the absence and pres-
ence of Ni(II) complex (50 mM). A0 is the initial absorbance intensity, A is
the absorbance intensity corresponding to its temperature, Af is the
ﬁnal absorbance intensity.
108734 | RSC Adv., 2016, 6, 108726–108740Gel electrophoretic studies
The interaction of metal complexes with double stranded closed
circular plasmid DNA is usually monitored by agarose gel
electrophoresis. This assay allows assessment of DNA strand
cleavage by monitoring the conversion of untreated form (FI)
plasmid DNA into the nicked form (FII) and linear form (FIII) in
the case of DNA cleavage. Also, retardation of DNA indicates
covalent binding of the investigated compounds. Upon addition
of 1 to the plasmid, no strand scission was observed (Fig. 7,
lanes 2 and 3) at concentrations up to 1.5 mM in comparison to
the control (lane 1), indicating that DNA cleavage does not
present a mode of action of this Ni(II) complex, i.e. the complex
has no nuclease activity. Binding of the higher concentrations
of the complex to the DNA causes the retardation of the plasmid
forms in the gel. The electrophoretic pattern suggests that
changes in conformations of the plasmid were caused by the
binding of 1, and retardation of the migration of DNA through
the gel is observed for molecules which bind covalently to
DNA.93–95Evaluation of anticancer activity
Nickel hydrazone complexes have been extensively investigated
for anticancer properties15–29 but in general, the literature data
deals with their activity described by IC50 concentrations with
data obtained by mean of colorimetric assays. Such method-
ology provides only the information on how the applied
compound reduces number of viable cells in the treated pop-
ulation with regard to non-treated control for a specic time of
incubation, therefore, calculated IC50 value gives an indication
on antiproliferative activity of investigated treatment, but not
on how the treatment aﬀected cell proliferation: by triggering
apoptotic or necrotic cell death, due to prolongation of mitotic
cycle with delayed population growth, or by induction of cell
dormancy. In this study, the method employed for assessment
of anticancer activity was Annexin V/PI double staining assay,
which allows accurate qualitative and quantitative discrimina-
tion of cell death in terms of apoptosis and necrosis. It also
enables us to observe if the compound concentration-
dependently introduces treated cells from initial to advancedFig. 7 Results of agarose gel electrophoresis of interaction of pUC19
with 1. Lane 1 – control plasmid pUC19; lane 2, 3, 4, 5 and 6 – plasmid
pUC19 with 1 mM, 1.5 mM, 2 mM, 2.5 mM and 3 mM of the complex,
respectively.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinephases of apoptotic death, which provides information on
concentration-response relationship with preliminary insight
into the span of therapeutic index. Besides these advantages,
the method of our choice presents one limitation: it is not
possible to directly compare activity of 1 to other nickel
complexes that were evaluated with colorimetric assays.
Anticancer activity of 1 can be compared with activity of
CDDP that is widely used for the treatment of broad-spectrum
malignancies. Aside from the fact that both 1 and CDDP are
metal complexes, those also share the same square-planar
geometry with d8 electronic conguration of divalent metalFig. 8 Types of cell death and cell cycle changes in THP-1 cell line indu
THP-1 cells treated with 1 during 24 h (A), and during 6 h (B). In Annexin V
left quadrant), cells in early phase of apoptotic death (Annexin V single-st
death (double-stained cells, upper right quadrant), and necrotic cells (
diﬀerent periods of incubation in cells treated with 1 and CDDP applied at
and G2/M phases were determined according to non-treated control po
cycle changes are expressed as the mean  SD of two replicates from i
This journal is © The Royal Society of Chemistry 2016ions. The mechanism of CDDP anticancer activity has been
studied for a long time, with new surprising discoveries even 30
years aer the main breakthrough in its understanding. Treiber
et al.96 described the relation between DNA crosslinking by
CDDP with high mobility group domain proteins and the
consequently aﬀected processes of transcription, replication
and DNA repair, and their context of “transcription factor
hijacking” is still considered the principal mechanism of CDDP
activity. Nevertheless, it has been proven that CDDP also
induces formation of reactive oxygen species,97,98 chromosomal
structural alterations,99 down-regulation of microRNAced by the treatment with 1. Results of Annexin V/PI double staining of
/PI dot plots cells are discriminated as viable (non-stained cells, lower
ained cells, lower right quadrant), cells in advanced phases of apoptotic
PI single-stained cells, upper left quadrant). Cell cycle changes after
their ED50 concentrations (C). Incidences of cells found at the G0/G1, S
pulation. Results of Annexin V/PI staining after 24 h treatment and cell
ndependent experiments.
RSC Adv., 2016, 6, 108726–108740 | 108735
Fig. 9 Role of caspases activation in apoptotic death of THP-1 cells
after 6 h treatment with 1 applied at ED50 concentration. Percentage of
apoptosis inhibition due to co-incubation of treated cells with pan-
caspase inhibitor Z-VAD-fmk (A), and relative change of caspase-8 and
-9 activity in treated cells computed in regard to non-treated control
(B). Both results are expressed as the mean  SD of two replicated
from independent experiments.
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View Article Onlineexpression,100 and interferes with intracellular calcium
signaling.101–103 Some of thesemechanisms are cell type-specic,
some concentration- and/or time-dependent, however, they
vindicate various cell cycle changes induced by CDDP treatment
in diﬀerent malignant cell lines. We have previously published
results of CDDP activity on both THP-1 and AsPC-1 cell lines,56
and herein we have investigated the activity of 1 in regards to
CDDP.
Activity of 1 was rstly investigated on THP-1 cell line.
Treatment involved 24 h incubation with 1 applied in a range of
six concentrations (1–100 mM). For THP-1 cells 1 induced strong
apoptotic response (Fig. 8A), with evidentially accelerating,
concentration-dependent accumulation of cells from the early
phase (Annexin V single-stained), to the advanced phases of
apoptotic death (Annexin V/PI double-stained cells). At the same
time, percentage of necrotic cells remained at the level of
untreated control throughout the concentration range. Gradual
evolution of apoptotic death was conrmed at 6 h incubation of
THP-1 cells with 1, when Annexin V single-stained cells were the
dominant events in the samples subjected to concentrations
which at 24 h treatment resulted in extensive percentage of late
apoptosis (Fig. 8B). On the other hand, CDDP at 24 h caused
concentration-dependent accumulation of THP-1 cells in the
early phase of apoptotic death while just a small percent of
them transitioned to the execution phase, even in the samples
subjected to the highest applied concentration.56
Concentration-response curve that describes activity of 1 is
plotted with lower ED50 concentration (10  3 mM, Fig. S10,
ESI†) than CDDP (17.8  0.2 mM).56
Although 1 and CDDP induce diﬀerent apoptotic responses
in THP-1 cell line, changes in cell cycle progression recorded
within 24 h incubation share some similarities (Fig. 8C). First,
within the rst 12 h, both compounds induced accumulation of
cells in the G0/G1 phase. This eﬀect was notably prominent in
the samples treated with 1, accompanied with reduced
percentage of cells in both S and G2/M phases. Second, at 12 h
incubation both compounds caused accumulation of treated
cells in the S phase, which at this point was markedly more
intensive in the samples treated with CDDP. Nevertheless,
distribution of treated cells at 24 h has nally conrmed the
assumption aer Annexin-V/PI analysis (Fig. 8A): while cells
treated with 1 were still slightly accumulated in the S phase,
those subjected to CDDP ended in the G1-to-S block, which
clearly dened that those two compounds do not share the
same mechanism of activity. Therefore, CDDP at 24 h acts as an
anti-proliferative agent rather than a pro-apoptotic one,
although it is not be possible to designate if AnnexinV single-
stained cells in CDDP-treated samples will end up in
apoptosis or necrosis. On the other hand, treatment with 1
easily triggers apoptosis within several hours of incubation, and
more important, eﬃciently drives THP-1 cells through the
process of apoptotic death. Current results are opposite to those
previously published for CDDP using the same biological
models and experimental conditions.56 The prominent charac-
teristic of CDDP activity is its interstrand cross-linking to DNA.
Although interstrand cross-links account for only a few
percentages of all CDDP adducts those are the crucial for DNA108736 | RSC Adv., 2016, 6, 108726–108740unwinding, activation of complex repair pathways with cell
cycle arrest at the S phase, and nally apoptotic death.104,105
Those reasons explain the delayed onset of apoptosis in cells
treated with CDDP compared to the eﬀect of 1.56 The decisive
issue that conrms distinction between mechanisms of CDDP
and 1 activities is the results of pUC19 electrophoresis, where 1
induced only a retardation of supercoiled form contrary to
massively unwound form seen in the presence of CDDP.106
Previously, we described the activity of caspases in cells
treated with CDDP.56 Briey, co-treatment of THP-1 cells with
CDDP and pan-caspase inhibitor Z-VAD-fmk revealed that
apoptosis induced by CDDP was not exclusively caspase-
dependent. Also, treatment of THP-1 cells with CDDP for 6 h
did not induce activation of either caspase-8 or caspase-947.
When THP-1 cells were co-incubated with Z-VAD-fmk and 1,
average of 35 3% of apoptotic events were inhibited compared
to the samples treated with 1 only (Fig. 9A). We also calculated
percentages of reduced events in early and late phases of
apoptotic death and that result undoubtedly revealed that the
inhibition of caspases activity primarily prevented initiation ofThis journal is © The Royal Society of Chemistry 2016
Fig. 10 Types of cell death and cell cycle changes in AsPC-1 cell line
induced by the treatment with 1 during 24 h incubation. In Annexin V/
PI dot plots (left panel) cells are discriminated as viable (non-stained
cells, lower left quadrant), cells in early phase of apoptotic death
(Annexin V single-stained cells, lower right quadrant), cells in advanced
phases of apoptotic death (double-stained cells, upper right quadrant),
and necrotic cells (PI single-stained cells, upper left quadrant). Cell
cycle changes (right panel) were determined as percentage of cells at
the G0/G1, S and G2/M phases of mitotic division according to non-
treated control population. All results are expressed as percentages of
one replicate.
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View Article Onlineapoptotic death in THP-1 cells rather than it hampered its
execution (70  14% of early apoptotic events inhibited vs. 26 
7% late apoptotic events). It is particularly interesting that co-
treatment with Z-VAD-fmk did not stimulate incidence of
necrotic death that could be expected due to interrupted chain
of cascade interactions, quite on the contrary necrosis was also
reduced in a high percentage (78  8%). This indicates that
cells, withheld from entering apoptosis due to inhibition of
caspases activity, do not end in necrosis. This further refers to
the mechanism by which 1 triggers apoptotic process, that does
not include substantial damage of cellular integrity, but
involves an initiation of cascade interactions with caspase
activation at the very onset.
Additional evaluation of caspases activity revealed that
treatment with 1 induced activation of caspase-8 in THP-1 cells
(Fig. 9B). In regard to untreated control, 357  40% of treated
cells were expressing activated caspase-8 only, while 78  18%
cells were expressing activated caspase-9. Apparently, due to the
cross-talk activation between two apoptotic pathways, 217 
71% of treated cells displayed activated both caspase-8 and -9.
Prevailing activation of caspase-8 demonstrates the 1 triggered
apoptotic death either by activation of death receptor signaling
cascade107 or by endoplasmic reticulum stress.108 This nding
additionally supports the diﬀerence between mechanisms of
CDDP and 1 activity.
When activation of caspase-8 was identied as mechanism
responsible for triggering of apoptosis in THP-1 cells treated
with 1, we hesitated to evaluate its activity on AsPC-1 cells
since it was previously shown that this cell line is low
expressing Fas ligand that might be involved in the initiation
of apoptotic death.109 CDDP did not show signicant activity
on AsPC-1 cells.56 Even more, while arrest at the S phase was
seen only aer treatment with the lowest applied concentra-
tion of CDDP that was not accompanied with apoptotic
response, percentages of cells at the cell cycle phases in
samples treated with higher concentrations barely varied
compared to untreated control. As expected, treatment of
AsPC-1 cells with 1 did not aﬀect their survival (Fig. 10),
however, changes in cell cycle distribution were far more
impressive than those induced by CDDP. It is important to
notice that these cells are poorly diﬀerentiated, referred to as
Cancer Stem Cells (CSCs).110 CSCs, also named as tumor-
initiating or tumor-propagating cells, are rare immortal cells
within the tumor bulk that possess a number of biological
properties that distinguish them from remaining tumor cells,
such as resistance to treatment and evasion of cell death by
ability to conceal into the state of dormancy,111 and that was
observed in the samples treated with 1. Contrary to CDDP, 1
evoked accumulation of AsPC-1 cells at the S phase only in the
samples treated with 1 and 10 mM, but higher concentrations
drove them toward G0/G1 block not accompanied with
increase of either apoptotic or necrotic events. While AsPC-1
cells were obviously unaﬀected by the treatment with CDDP,
the same cell line was provoked by 1 and its mechanism of
activity, escaping apoptosis by hiding in the state of dormancy,
at least for the rst 24 h of incubation.This journal is © The Royal Society of Chemistry 2016Conclusions
Novel nickel(II) square-planar hydrazone complex 1 was
synthesized and characterized, and its geometry was optimized
by DFT calculations. IR spectroscopy results indicate asym-
metrical coordination of ligand's arms, which was also found inRSC Adv., 2016, 6, 108726–108740 | 108737
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View Article Onlinethe solution, as evidenced by NMR spectroscopy. Investigation
of thermal stability of 1 showed that it is thermally stable at
temperatures below 160 C, while the initial degradation
processes in air and nitrogen exhibit relatively high values of
overall apparent activation energy of 250–300 and 1150–1200 kJ
mol1, respectively. This property makes the complex suitable
for long-term storage at normal ambient temperatures, with
easier potential medical and biological usage.
Current investigation provided experimental validation for
the ability of 1 to covalently bind to DNA, which is also well-
known feature of CDDP. However, the series of our results
revealed that the mechanism of anticancer activity for these two
compounds is completely diﬀerent. Aer 24 h incubation on
THP-1 cells 1 induces powerful apoptotic response accompa-
nied with slight accumulation of cells at the S phase of mitotic
division. Apoptosis driven by 1 is partially caspase-dependent
with dominantly activated caspase-8. Therefore, the results
presented here strongly indicate that 1 has a diﬀerent, more
eﬃcient mode of anticancer activity than CDDP. Concentration-
dependent shi in the cell cycle distribution of AsPC-1 cells,
experimentally conrmed covalent binding to DNA, and acti-
vation of caspase-8 strongly indicates that 1 exhibits at least two
mechanisms of anticancer activity. The induced caspase-8
activation by 1 sets it as a primary interest in any further
investigation.Acknowledgements
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